The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Open accessAbstract
Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and regulates the survival and metastasis of cancer cells. EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear. Here we show that the expression and function of EZH2 in cancer cell lines are inhibited by microRNA-101 (miR-101). Analysis of human prostate tumors revealed that miR-101 expression decreases during cancer progression, paralleling an increase in EZH2 expression. One or both of the two genomic loci encoding miR-101 were somatically lost in 37.5% of clinically localized prostate cancer cells (6 of 16) and 66.7% of metastatic disease cells (22 of 33). We propose that the genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Prediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020363 · Cited by 3,796
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citationPolycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,514
Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R. M., Chevalier, B., Johnstone, S. E., Cole, M. F., Isono, K.-I., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,268
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Self-citation
Cited by
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
“miR-101 is often downregulated in cancer, leading to overexpression of enhancer of zeste 2 (EZH2”
BackgroundEpigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Metastasis: from dissemination to organ-specific colonization
Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2622 · Cited by 2,649
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Linking DNA methylation and histone modification: patterns and paradigms
Cedar, H., & Bergman, Y. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2540 · Cited by 2,267
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,234
Self-citationEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
“Under these conditions, the contribution from the enzyme concentration becomes relatively small (see equation (1)) and accurate estimates of Ki can be calculated(29).”
BackgroundDivergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Self-citationDi Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
“Furthermore, miR101, a negative regulator of EZH2 , is frequently deleted in prostate cance”
BackgroundTargeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Jansson, M. D., & Lund, A. H. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.006 · Cited by 1,099
Lujambio, A., & Lowe, S. W. (2012) · Nature · doi:10.1038/nature10888 · Cited by 1,084
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 910
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
MicroRNAs — the micro steering wheel of tumour metastases
Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S., & Calin, G. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2619 · Cited by 749
MicroRNA function in cancer: oncogene or a tumor suppressor?
Shenouda, S. K., & Alahari, S. K. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9188-5 · Cited by 682
Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
Berdasco, M., & Esteller, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.005 · Cited by 618
The role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611
Sato, F., Tsuchiya, S., Meltzer, S. J., & Shimizu, K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08089.x · Cited by 588
Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
Sauvageau, M., & Sauvageau, G. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.002 · Cited by 586
Polycomb group proteins: navigators of lineage pathways led astray in cancer
Bracken, A. P., & Helin, K. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2736 · Cited by 523
Non-coding RNAs as direct and indirect modulators of epigenetic regulation
Peschansky, V. J., & Wahlestedt, C. (2014) · Epigenetics · doi:10.4161/epi.27473 · Cited by 516
EMT as the ultimate survival mechanism of cancer cells
Tiwari, N., Gheldof, A., Tatari, M., & Christofori, G. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.013 · Cited by 512
Regulation of proteasome assembly and activity in health and disease
Rousseau, A., & Bertolotti, A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0040-z · Cited by 510
Tiwari, N., Tiwari, V. K., Waldmeier, L., Balwierz, P. J., Arnold, P., Pachkov, M., Meyer-Schaller, N., Schübeler, D., van Nimwegen, E., & Christofori, G. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.020 · Cited by 484
McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 483
MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., Hamdy, F. C., Kallioniemi, O., Mengual, L., Schlomm, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.044 · Cited by 469
Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., & Lichter, P. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3554 · Cited by 453
MicroRNAs: Novel regulators in the hallmarks of human cancer
Ruan, K., Fang, X., & Ouyang, G. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.031 · Cited by 447
MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases
Cortez, M. A., & Calin, G. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902932889 · Cited by 436
Kashyap, V., Rezende, N. C., Scotland, K. B., Shaffer, S. M., Persson, J. L., Gudas, L. J., & Mongan, N. P. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0113 · Cited by 436
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
Comet, I., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.83 · Cited by 432
Zhao, E., Maj, T., Kryczek, I., Li, W., Wu, K., Zhao, L., Wei, S., Crespo, J., Wan, S., Vatan, L., et al. (2016) · Nature Immunology · doi:10.1038/ni.3313 · Cited by 405
Self-citationUnravelling the complexity of metastasis — molecular understanding and targeted therapies
Sethi, N., & Kang, Y. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3125 · Cited by 397
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 395
Yang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C. V., Zhao, Y., Reynolds, S., Cheng, H., Rupaimoole, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.020 · Cited by 394
Autophagy as a molecular target for cancer treatment
Kocaturk, N. M., Akkoc, Y., Kig, C., Bayraktar, O., Gozuacik, D., & Kutlu, O. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.011 · Cited by 387
Friedman, J. M., Liang, G., Liu, C.-C., Wolff, E. M., Tsai, Y. C., Ye, W., Zhou, X., & Jones, P. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3114 · Cited by 382
Zheng, F., Liao, Y.-J., Cai, M.-Y., Liu, Y.-H., Liu, T.-H., Chen, S.-P., Bian, X.-W., Guan, X.-Y., Lin, M. C., Zeng, Y.-X., et al. (2012) · Gut · doi:10.1136/gut.2011.239145 · Cited by 376
Martinez-Garcia, E., Popovic, R., Min, D.-J., Sweet, S. M. M., Thomas, P. M., Zamdborg, L., Heffner, A., Will, C., Lamy, L., Staudt, L. M., et al. (2011) · Blood · doi:10.1182/blood-2010-07-298349 · Cited by 360
Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., Ustun, C., Rao, R., Fernandez, P., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213496 · Cited by 356
Juan, A. H., Kumar, R. M., Marx, J. G., Young, R. A., & Sartorelli, V. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.008 · Cited by 354
Li, Z., Hou, P., Fan, D., Dong, M., Ma, M., Li, H., Yao, R., Li, Y., Wang, G., Geng, P., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2016.95 · Cited by 339
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
Kim, W., Bird, G. H., Neff, T., Guo, G., Kerenyi, M. A., Walensky, L. D., & Orkin, S. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1331 · Cited by 338
The role of EZH2 in tumour progression
Chang, C.-J., & Hung, M.-C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.551 · Cited by 332
Yamagishi, M., Nakano, K., Miyake, A., Yamochi, T., Kagami, Y., Tsutsumi, A., Matsuda, Y., Sato-Otsubo, A., Muto, S., Utsunomiya, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.015 · Cited by 329
Targeting DNA methylation for epigenetic therapy
Yang, X., Lay, F., Han, H., & Jones, P. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.001 · Cited by 326
miRNA control of tumor cell invasion and metastasis
Baranwal, S., & Alahari, S. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25014 · Cited by 316
microRNA‐101 is a potent inhibitor of autophagy
Frankel, L. B., Wen, J., Lees, M., Høyer‐Hansen, M., Farkas, T., Krogh, A., Jäättelä, M., & Lund, A. H. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.331 · Cited by 312
Pan, Z., Sun, X., Shan, H., Wang, N., Wang, J., Ren, J., Feng, S., Xie, L., Lu, C., Yuan, Y., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.094524 · Cited by 312
Interplay between microRNAs and the epigenetic machinery: An intricate network
Iorio, M. V., Piovan, C., & Croce, C. M. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.005 · Cited by 306
Histone methyltransferases in cancer
Albert, M., & Helin, K. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.10.007 · Cited by 306
The Redox Basis of Epigenetic Modifications: From Mechanisms to Functional Consequences
Cyr, A. R., & Domann, F. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3492 · Cited by 297
Bao, B., Ali, S., Banerjee, S., Wang, Z., Logna, F., Azmi, A. S., Kong, D., Ahmad, A., Li, Y., Padhye, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2182 · Cited by 297
Koh, C. M., Bieberich, C. J., Dang, C. V., Nelson, W. G., Yegnasubramanian, S., & De Marzo, A. M. (2010) · Genes & Cancer · doi:10.1177/1947601910379132 · Cited by 296
Wang, X., Li, M., Wang, Z., Han, S., Tang, X., Ge, Y., Zhou, L., Zhou, C., Yuan, Q., & Yang, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.596866 · Cited by 292
Self-citationEpigenetic regulation in human melanoma: past and future
Sarkar, D., Leung, E. Y., Baguley, B. C., Finlay, G. J., & Askarian-Amiri, M. E. (2015) · Epigenetics · doi:10.1080/15592294.2014.1003746 · Cited by 289
Regulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
Epigenetic Mechanisms in Inflammation
Bayarsaihan, D. (2011) · Journal of Dental Research · doi:10.1177/0022034510378683 · Cited by 287
Au, S. L.-K., Wong, C. C.-L., Lee, J. M.-F., Fan, D. N.-Y., Tsang, F. H., Ng, I. O.-L., & Wong, C.-M. (2012) · Hepatology · doi:10.1002/hep.25679 · Cited by 287
Alajez, N. M., Lenarduzzi, M., Ito, E., Hui, A. B. Y., Shi, W., Bruce, J., Yue, S., Huang, S. H., Xu, W., Waldron, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2754 · Cited by 283
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2
Chen, S., Bohrer, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., Bagchi, A., Simon, J. A., & Huang, H. (2010) · Nature Cell Biology · doi:10.1038/ncb2116 · Cited by 281
Nagarsheth, N., Peng, D., Kryczek, I., Wu, K., Li, W., Zhao, E., Zhao, L., Wei, S., Frankel, T., Vatan, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1938 · Cited by 271
Micromarkers: miRNAs in cancer diagnosis and prognosis
Ferracin, M., Veronese, A., & Negrini, M. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.11 · Cited by 266
Chen, D.-L., Ju, H.-Q., Lu, Y.-X., Chen, L.-Z., Zeng, Z.-L., Zhang, D.-S., Luo, H.-Y., Wang, F., Qiu, M.-Z., Wang, D.-S., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0420-1 · Cited by 262
MicroRNA regulation of autophagy
Frankel, L. B., & Lund, A. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs266 · Cited by 256
Cao, P., Deng, Z., Wan, M., Huang, W., Cramer, S. D., Xu, J., Lei, M., & Sui, G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-108 · Cited by 255
The omniscient placenta: Metabolic and epigenetic regulation of fetal programming
Nugent, B. M., & Bale, T. L. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.09.001 · Cited by 222
Score, J., Hidalgo-Curtis, C., Jones, A. V., Winkelmann, N., Skinner, A., Ward, D., Zoi, K., Ernst, T., Stegelmann, F., Döhner, K., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367243 · Cited by 177
MicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages
Zhu, Q.-Y., Liu, Q., Chen, J.-X., Lan, K., & Ge, B.-X. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000798 · Cited by 152
“The aberrant expression profile of miR-101 also is shown in the majority of cancer cell lines and cancer tissues examined (44), suggesting that it may act as a cancer-related miRNA.”
BackgroundKunderfranco, P., Mello-Grand, M., Cangemi, R., Pellini, S., Mensah, A., Albertini, V., Malek, A., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010547 · Cited by 143
MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes
Fujii, S., Tokita, K., Wada, N., Ito, K., Yamauchi, C., Ito, Y., & Ochiai, A. (2011) · Oncogene · doi:10.1038/onc.2011.118 · Cited by 137
Interplay between Epigenetics and Genetics in Cancer
Choi, J. D., & Lee, J.-S. (2013) · Genomics & Informatics · doi:10.5808/gi.2013.11.4.164 · Cited by 131
Comprehensive survey of human brain microRNA by deep sequencing
Shao, N.-Y., Hu, H. Y., Yan, Z., Xu, Y., Hu, H., Menzel, C., Li, N., Chen, W., & Khaitovich, P. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-409 · Cited by 131
Smits, M., Mir, S. E., Nilsson, R. J. A., van der Stoop, P. M., Niers, J. M., Marquez, V. E., Cloos, J., Breakefield, X. O., Krichevsky, A. M., Noske, D. P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016282 · Cited by 118
Hudson, R. S., Yi, M., Esposito, D., Glynn, S. A., Starks, A. M., Yang, Y., Schetter, A. J., Watkins, S. K., Hurwitz, A. A., Dorsey, T. H., et al. (2013) · Oncogene · doi:10.1038/onc.2012.424 · Cited by 98
MicroRNAs and glioblastoma; the stem cell connection
Godlewski, J., Newton, H. B., Chiocca, E. A., & Lawler, S. E. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.71 · Cited by 86
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“EZH2 expression is essential for cancer survival (Varambally et al., 2008).”
BackgroundCai, S., Chen, R., Li, X., Cai, Y., Ye, Z., Li, S., Li, J., Huang, H., Peng, S., Wang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2880 · Cited by 76
Interplay between the miRNome and the epigenetic machinery: Implications in health and disease
Poddar, S., Kesharwani, D., & Datta, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25819 · Cited by 57
A model explaining mRNA level fluctuations based on activity demands and RNA age
Xu, Z., & Asakawa, S. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009188 · Cited by 9
Metadata
- Authors
- Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., Brenner, J. C., Yu, J., Kim, J. H., Han, B., Tan, P., Kumar-Sinha, C., Lonigro, R. J., Palanisamy, N., Maher, C. A., & Chinnaiyan, A. M.
- Venue
- Science
- Published
- 2008-12-12
- Volume
- 322
- Issue
- 5908
- Pages
- 1695-1699
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2040182688
- Cited by
- 1,052
- References
- 26
- FWCI
- 23.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.